Dentsply Sirona Inc. (XRAY) is a dental products and technologies company, and its analyst coverage is broad but heavily weighted toward a neutral view. Reviewing roughly a dozen current, individually attributed targets from firms including Bank of America, UBS, Stifel, Baird, Barrington, Evercore ISI, Wells Fargo, Piper Sandler, Mizuho, Barclays, Leerink Partners, and BMO Capital produces a range of roughly $10 to $17 and an arithmetic mean of about $13, which serves as the central target here.
Views differ sharply. The more bullish targets ($17 from Bank of America and UBS) assume a multi-year recovery takes hold, while cautious targets ($10 from Leerink and BMO) reflect concern about demand and a slower "return to growth." Most firms cluster in the low-to-mid teens with Hold or Market Perform ratings. This is consistent with published aggregate figures that land in the low-to-mid $12 to $13 range, but the central figure is a calculated mean of individual targets, not an official published consensus.
At a recent close of $9.73, reaching $13 would require a gain of roughly 34% — a substantial move for a large-cap specialty manufacturer. The stock has been under pressure, trading well below its 52-week high of $14.76 and near its 52-week low of $8.32.
The path toward the target depends on whether the company can stabilize revenue (recently around $3.6 billion annually) and expand margins. Analysts expect a modest rebound in EPS for fiscal 2026, but revenue is still forecast to decline year over year. With the next quarterly report due shortly, near-term direction will hinge on actual demand and guidance rather than valuation alone.
The shares remain in a longer-term downtrend, with the 52-week high near $14.76 acting as a major overhead reference and the 52-week low near $8.32 as key support. Between the current price and the $13 target, the stock must first reclaim levels around $10 to $11, which have served as recent resistance and as prior support, before approaching the $12 to $13 zone. A decisive move back above $13 would put the stock closer to the mid-teens area where it traded earlier in 2026.
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms vary. The most important near-term catalyst is the company's next earnings report and guidance update, followed by any analyst revisions to targets and ratings. Investors should also watch macroeconomic signals for dental-patient traffic and elective-procedure demand, leadership announcements, and changes to the company's turnaround timeline. None of these guarantees the stock reaches $13, but each will shape the probability-weighted outlook.
For traders who prefer a systematic approach, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning alone. Traders looking to complement fundamental research on names like Dentsply Sirona can use these signals to stay ahead of fast-moving market changes.
The central $13 target for Dentsply Sirona (XRAY) reflects the arithmetic mean of roughly a dozen current analyst targets ranging from $10 to $17, implying a substantial gain of about 34% from the latest close near $9.73. The bull case rests on dental-market stabilization, an earnings recovery, and low expectations, while the bear case points to weak demand, declining revenue, and ongoing leadership turnover. With most analysts holding a neutral stance and targets spread widely, the path to $13 is far from assured. Investors should watch the upcoming earnings report, guidance, and any subsequent analyst revisions before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To XRAY | 1D Price Change % | ||
|---|---|---|---|---|
| XRAY | 100% | -0.87% | ||
| NVST - XRAY | 62% Loosely correlated | -0.69% | ||
| ALGN - XRAY | 60% Loosely correlated | +0.81% | ||
| QDEL - XRAY | 50% Loosely correlated | +1.13% | ||
| KIDS - XRAY | 48% Loosely correlated | -0.71% | ||
| STE - XRAY | 46% Loosely correlated | +4.29% | ||
More | ||||
| Ticker / NAME | Correlation To XRAY | 1D Price Change % |
|---|---|---|
| XRAY | 100% | -0.87% |
| Pharmaceuticals: Other industry (49 stocks) | 58% Loosely correlated | +0.20% |
| Pharmaceuticals industry (151 stocks) | 3% Poorly correlated | +0.11% |